Genmab — Director's Dealing 2016

Dec 15, 2016

Company Announcement

Copenhagen, Denmark; December 15, 2016 – In accordance with Article 19 of
Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,
the persons below have given Genmab A/S (Nasdaq Copenhagen: GEN) power of
attorney on their behalf to publish and report their trading in Genmab shares
and related instruments, as follows:

1. Details of the person discharging managerial responsibilities /
   person closely associated

---

a) Name Mats Pettersson

2. Reason for the notification

a) Position/status Chairman of the Board of Directors

b) Initial notification/Amendment Initial notification

1. Details of the issuer, emission allowance market participant,
   auction platform, auctioneer or auction monitor

---

a) Name Genmab A/S

b) LEI-code N/A

1. Details of the transaction(s): section to be repeated for
   (i) each type of instrument; (ii) each type of transaction;
   (iii) each date; and (iv) each place where transactions have been conducted

---

a) Description of the financial Restricted Stock Units related to
instrument, type of instrument shares of Genmab A/S
Identification code DK0010272202

---

b) Nature of the transaction Grant of Restricted Stock Units

c) Price(s) and volume(s) Price(s) Volume(s)

                                        DKK 0.00                         786

---

d) Aggregated information
- Aggregated volume
- Price

---

e) Date of the transaction 2016-12-15

f) Place of the transaction Outside the market

1. Details of the person discharging managerial responsibilities /
   person closely associated

---

a) Name Anders Gersel Pedersen

2. Reason for the notification

a) Position/status Member of the Board of Directors

b) Initial notification/Amendment Initial notification

1. Details of the issuer, emission allowance market participant,
   auction platform, auctioneer or auction monitor

---

a) Name Genmab A/S

b) LEI-code N/A

1. Details of the transaction(s): section to be repeated for
   (i) each type of instrument; (ii) each type of transaction;
   (iii) each date; and (iv) each place where transactions have been conducted

---

a) Description of the financial Restricted Stock Units related to
instrument, type of instrument shares of Genmab A/S
Identification code DK0010272202

---

b) Nature of the transaction Grant of Restricted Stock Units

c) Price(s) and volume(s) Price(s) Volume(s)

                                        DKK 0.00                         589

---

d) Aggregated information
- Aggregated volume
- Price

---

e) Date of the transaction 2016-12-15

f) Place of the transaction Outside the market

1. Details of the person discharging managerial responsibilities /
   person closely associated

---

a) Name Dan Bruno

2. Reason for the notification

a) Position/status Member of the Board of Directors

b) Initial notification/Amendment Initial notification

1. Details of the issuer, emission allowance market participant,
   auction platform, auctioneer or auction monitor

---

a) Name Genmab A/S

b) LEI-code N/A

1. Details of the transaction(s): section to be repeated for
   (i) each type of instrument; (ii) each type of transaction;
   (iii) each date; and (iv) each place where transactions have been conducted

---

a) Description of the financial Restricted Stock Units related to shares
instrument, type of instrument of Genmab A/S
Identification code DK0010272202

---

b) Nature of the transaction Grant of Restricted Stock Units (partly
as employee of Genmab US, Inc., partly
as board member)

---

c) Price(s) and volume(s) Price(s) Volume(s)

                                    DKK 0.00       1,091 (as employee)

---

                                    DKK 0.00       393 (as board member)

---

d) Aggregated information 1,484
- Aggregated volume DKK 0.00
- Price

---

e) Date of the transaction 2016-12-15

f) Place of the transaction Outside the market

1. Details of the person discharging managerial responsibilities /
   person closely associated

---

a) Name Pernille Erenbjerg

2. Reason for the notification

a) Position/status Member of the Board of Directors

b) Initial notification/Amendment Initial notification

1. Details of the issuer, emission allowance market participant,
   auction platform, auctioneer or auction monitor

---

a) Name Genmab A/S

b) LEI-code N/A

1. Details of the transaction(s): section to be repeated for
   (i) each type of instrument; (ii) each type of transaction;
   (iii) each date; and (iv) each place where transactions have been conducted

---

a) Description of the financial Restricted Stock Units related to
instrument, type of instrument shares of Genmab A/S
Identification code DK0010272202

---

b) Nature of the transaction Grant of Restricted Stock Units

c) Price(s) and volume(s) Price(s) Volume(s)

                                        DKK 0.00                         393

---

d) Aggregated information
- Aggregated volume
- Price

---

e) Date of the transaction 2016-12-15

f) Place of the transaction Outside the market

1. Details of the person discharging managerial responsibilities /
   person closely associated

---

a) Name Rick Hibbert

2. Reason for the notification

a) Position/status Member of the Board of Directors

b) Initial notification/Amendment Initial notification

1. Details of the issuer, emission allowance market participant,
   auction platform, auctioneer or auction monitor

---

a) Name Genmab A/S

b) LEI-code N/A

1. Details of the transaction(s): section to be repeated for
   (i) each type of instrument; (ii) each type of transaction;
   (iii) each date; and (iv) each place where transactions have been conducted

---

a) Description of the financial Restricted Stock Units related to shares
instrument, type of instrument of Genmab A/S
Identification code DK0010272202

---

b) Nature of the transaction Grant of Restricted Stock Units (partly
as employee of Genmab B.V., partly as
board member)

---

c) Price(s) and volume(s) Price(s) Volume(s)

                                    DKK 0.00       65 (as employee)

---

                                    DKK 0.00       393 (as board member)

---

d) Aggregated information 458
- Aggregated volume DKK 0.00
- Price

---

e) Date of the transaction 2016-12-15

f) Place of the transaction Outside the market

1. Details of the person discharging managerial responsibilities /
   person closely associated

---

a) Name Peter Storm Kristensen

2. Reason for the notification

a) Position/status Member of the Board of Directors

b) Initial notification/Amendment Initial notification

1. Details of the issuer, emission allowance market participant,
   auction platform, auctioneer or auction monitor

---

a) Name Genmab A/S

b) LEI-code N/A

1. Details of the transaction(s): section to be repeated for
   (i) each type of instrument; (ii) each type of transaction;
   (iii) each date; and (iv) each place where transactions have been conducted

---

a) Description of the financial Restricted Stock Units related to shares
instrument, type of instrument of Genmab A/S
Identification code DK0010272202

---

b) Nature of the transaction Grant of Restricted Stock Units (partly
as employee of Genmab A/S, partly as
board member)

---

c) Price(s) and volume(s) Price(s) Volume(s)

                                    DKK 0.00       115 (as employee)

---

                                    DKK 0.00       393 (as board member)

---

d) Aggregated information 508
- Aggregated volume DKK 0.00
- Price

---

e) Date of the transaction 2016-12-15

f) Place of the transaction Outside the market

1. Details of the person discharging managerial responsibilities /
   person closely associated

---

a) Name Burton G. Malkiel

2. Reason for the notification

a) Position/status Member of the Board of Directors

b) Initial notification/Amendment Initial notification

1. Details of the issuer, emission allowance market participant,
   auction platform, auctioneer or auction monitor

---

a) Name Genmab A/S

b) LEI-code N/A

1. Details of the transaction(s): section to be repeated for
   (i) each type of instrument; (ii) each type of transaction;
   (iii) each date; and (iv) each place where transactions have been conducted

---

a) Description of the financial Restricted Stock Units related to
instrument, type of instrument shares of Genmab A/S
Identification code DK0010272202

---

b) Nature of the transaction Grant of Restricted Stock Units

c) Price(s) and volume(s) Price(s) Volume(s)

                                        DKK 0.00                         393

---

d) Aggregated information
- Aggregated volume
- Price

---

e) Date of the transaction 2016-12-15

f) Place of the transaction Outside the market

1. Details of the person discharging managerial responsibilities /
   person closely associated

---

a) Name Paolo Paoletti

2. Reason for the notification

a) Position/status Member of the Board of Directors

b) Initial notification/Amendment Initial notification

1. Details of the issuer, emission allowance market participant,
   auction platform, auctioneer or auction monitor

---

a) Name Genmab A/S

b) LEI-code N/A

1. Details of the transaction(s): section to be repeated for
   (i) each type of instrument; (ii) each type of transaction;
   (iii) each date; and (iv) each place where transactions have been conducted

---

a) Description of the financial Restricted Stock Units related to
instrument, type of instrument shares of Genmab A/S
Identification code DK0010272202

---

b) Nature of the transaction Grant of Restricted Stock Units

c) Price(s) and volume(s) Price(s) Volume(s)

                                        DKK 0.00                         393

---

d) Aggregated information
- Aggregated volume
- Price

---

e) Date of the transaction 2016-12-15

f) Place of the transaction Outside the market

1. Details of the person discharging managerial responsibilities /
   person closely associated

---

a) Name Jan G. J. van de Winkel

2. Reason for the notification

a) Position/status President & Chief Executive
Officer

---

b) Initial notification/Amendment Initial notification

1. Details of the issuer, emission allowance market participant,
   auction platform, auctioneer or auction monitor

---

a) Name Genmab A/S

b) LEI-code N/A

1. Details of the transaction(s): section to be repeated for
   (i) each type of instrument; (ii) each type of transaction;
   (iii) each date; and (iv) each place where transactions have been conducted

---

a) Description of the financial Restricted Stock Units related to
instrument, type of instrument shares of Genmab A/S
Identification code DK0010272202

---

b) Nature of the transaction Grant of Restricted Stock Units

c) Price(s) and volume(s) Price(s) Volume(s)

                                        DKK 0.00                       5,819

---

d) Aggregated information
- Aggregated volume
- Price

---

e) Date of the transaction 2016-12-15

f) Place of the transaction Outside the market

1. Details of the person discharging managerial responsibilities /
   person closely associated

---

a) Name David A. Eatwell

2. Reason for the notification

a) Position/status Executive Vice President & Chief
Financial Officer

---

b) Initial notification/Amendment Initial notification

1. Details of the issuer, emission allowance market participant,
   auction platform, auctioneer or auction monitor

---

a) Name Genmab A/S

b) LEI-code N/A

1. Details of the transaction(s): section to be repeated for
   (i) each type of instrument; (ii) each type of transaction;
   (iii) each date; and (iv) each place where transactions have been conducted

---

a) Description of the financial Restricted Stock Units related to
instrument, type of instrument shares of Genmab A/S
Identification code DK0010272202

---

b) Nature of the transaction Grant of Restricted Stock Units

c) Price(s) and volume(s) Price(s) Volume(s)

                                        DKK 0.00                       3,634

---

d) Aggregated information
- Aggregated volume
- Price

---

e) Date of the transaction 2016-12-15

f) Place of the transaction Outside the market

1. Details of the person discharging managerial responsibilities /
   person closely associated

---

a) Name Jan G. J. van de Winkel

2. Reason for the notification

a) Position/status President & Chief Executive
Officer

---

b) Initial notification/Amendment Initial notification

1. Details of the issuer, emission allowance market participant,
   auction platform, auctioneer or auction monitor

---

a) Name Genmab A/S

b) LEI-code N/A

1. Details of the transaction(s): section to be repeated for
   (i) each type of instrument; (ii) each type of transaction;
   (iii) each date; and (iv) each place where transactions have been conducted

---

a) Description of the financial Warrants related to shares of Genmab
instrument, type of instrument A/S
Identification code DK0010272202

---

b) Nature of the transaction Grant of warrants

c) Price(s) and volume(s) Price(s) Volume(s)

                                        DKK 0.00                      17,941

---

d) Aggregated information
- Aggregated volume
- Price

---

e) Date of the transaction 2016-12-15

f) Place of the transaction Outside the market

1. Details of the person discharging managerial responsibilities /
   person closely associated

---

a) Name David A. Eatwell

2. Reason for the notification

a) Position/status Executive Vice President & Chief
Financial Officer

---

b) Initial notification/Amendment Initial notification

1. Details of the issuer, emission allowance market participant,
   auction platform, auctioneer or auction monitor

---

a) Name Genmab A/S

b) LEI-code N/A

1. Details of the transaction(s): section to be repeated for
   (i) each type of instrument; (ii) each type of transaction;
   (iii) each date; and (iv) each place where transactions have been conducted

---

a) Description of the financial Warrants related to shares of Genmab
instrument, type of instrument A/S
Identification code DK0010272202

---

b) Nature of the transaction Grant of warrants

c) Price(s) and volume(s) Price(s) Volume(s)

                                        DKK 0.00                      11,202

---

d) Aggregated information
- Aggregated volume
- Price

---

e) Date of the transaction 2016-12-15

f) Place of the transaction Outside the market

1. Details of the person discharging managerial responsibilities /
   person closely associated

---

a) Name Dan Bruno

2. Reason for the notification

a) Position/status Member of the Board of Directors

b) Initial notification/Amendment Initial notification

1. Details of the issuer, emission allowance market participant,
   auction platform, auctioneer or auction monitor

---

a) Name Genmab A/S

b) LEI-code N/A

1. Details of the transaction(s): section to be repeated for
   (i) each type of instrument; (ii) each type of transaction;
   (iii) each date; and (iv) each place where transactions have been conducted

---

a) Description of the financial Warrants related to shares of Genmab
instrument, type of instrument A/S
Identification code DK0010272202

---

b) Nature of the transaction Grant of warrants (as employee of
Genmab US, Inc., not as board
member)

---

c) Price(s) and volume(s) Price(s) Volume(s)

                                        DKK 0.00                       3,363

---

d) Aggregated information
- Aggregated volume
- Price

---

e) Date of the transaction 2016-12-15

f) Place of the transaction Outside the market

1. Details of the person discharging managerial responsibilities /
   person closely associated

---

a) Name Rick Hibbert

2. Reason for the notification

a) Position/status Member of the Board of Directors

b) Initial notification/Amendment Initial notification

1. Details of the issuer, emission allowance market participant,
   auction platform, auctioneer or auction monitor

---

a) Name Genmab A/S

b) LEI-code N/A

1. Details of the transaction(s): section to be repeated for
   (i) each type of instrument; (ii) each type of transaction;
   (iii) each date; and (iv) each place where transactions have been conducted

---

a) Description of the financial Warrants related to shares of Genmab
instrument, type of instrument A/S
Identification code DK0010272202

---

b) Nature of the transaction Grant of warrants (as employee of
Genmab B.V., not as board member)

---

c) Price(s) and volume(s) Price(s) Volume(s)

                                        DKK 0.00                         200

---

d) Aggregated information
- Aggregated volume
- Price

---

e) Date of the transaction 2016-12-15

f) Place of the transaction Outside the market

1. Details of the person discharging managerial responsibilities /
   person closely associated

---

a) Name Peter Storm Kristensen

2. Reason for the notification

a) Position/status Member of the Board of Directors

b) Initial notification/Amendment Initial notification

1. Details of the issuer, emission allowance market participant,
   auction platform, auctioneer or auction monitor

---

a) Name Genmab A/S

b) LEI-code N/A

1. Details of the transaction(s): section to be repeated for
   (i) each type of instrument; (ii) each type of transaction;
   (iii) each date; and (iv) each place where transactions have been conducted

---

a) Description of the financial Warrants related to shares of Genmab
instrument, type of instrument A/S
Identification code DK0010272202

---

b) Nature of the transaction Grant of warrants (as employee of
Genmab A/S, not as board member)

---

c) Price(s) and volume(s) Price(s) Volume(s)

                                        DKK 0.00                         354

---

d) Aggregated information
- Aggregated volume
- Price

---

e) Date of the transaction 2016-12-15

f) Place of the transaction Outside the market

About Genmab
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated antibody therapeutics for the
treatment of cancer. Founded in 1999, the company has two approved antibodies,
DARZALEX® (daratumumab) for the treatment of certain multiple myeloma
indications, and Arzerra® (ofatumumab) for the treatment of certain chronic
lymphocytic leukemia indications. Daratumumab is in clinical development for
additional multiple myeloma indications, non-Hodgkin’s lymphoma and solid
tumors. A subcutaneous formulation of ofatumumab is in development for
relapsing multiple sclerosis. Genmab also has a broad clinical and
pre-clinical product pipeline. Genmab's technology base consists of validated
and proprietary next generation antibody technologies - the DuoBody® platform
for generation of bispecific antibodies, and the HexaBody® platform which
creates effector function enhanced antibodies. The company intends to leverage
these technologies to create opportunities for full or co-ownership of future
products. Genmab has alliances with top tier pharmaceutical and biotechnology
companies. For more information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™;
the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody®
and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates.
DARZALEX® is a trademark of Janssen Biotech, Inc.

Company Announcement no. 58
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark